BIOINVEST Update – The Medicines Company (MDCO) – Amgen’s FOURIER Outcomes Trial Successful – After the close, AMGN announced the long-awaited results of the outcomes trial with Repatha – its PCSK9 monoclonal antibody.
The next-generation of cholesterol drugs were approved in 2016; these targeted drugs rapidly reduce LDL cholesterol in a wide variety of patients with cardiovascular disease, notes Jay Silverman, editor of the Medical Technology Stock Letter.
MTSL Issue 842 (dated 12/15/16) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ANTH #CBMG #INCY #MDCO
10 biotech companies ripe for a buyout, courtesy of Donald Trump (11-17-16)
Non-alcoholic steatohepatitis, or NASH, is one of the largest disease opportunities we have ever seen, explains John McCamant, editor of The Medical technology Stock Letter.
MTSL Issue 843 (dated 1/5/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #ANTH #INCY #IONS #MDCO
MTSL Issue 841 (dated 12/1/16) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #MDGL #SGMO
MTSL Issue 840 (dated 11/17/16) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ANTH #IONS #MDCO #NVAX #ZIOP
MTSL Issue 844 (dated 1/19/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #BMRN #CELG #INCY #IONS #MDCO #NKTR #PCRX #SGMO #ZIOP
This Top Pick for 2017 may very well have the best and broadest early-stage oncology pipeline with 12 drug development candidates, suggests John McCamant, editor The Medical Technology Stock Letter.
Health care stocks soared after the presidential election. A Trump victory represents the perfect storm for biotech investors, and we expect there to be an explosion of deal activity with the pro-business Trump administration. Learn more about the Trump Effect and how you can get in on the action.
The Medicines Company (MDCO) presented the details of the ORION-1 Phase II trial interim results of 501 patients given MDCO-PCSK-9si at a Late-Breaker Session at the AHA. MDCO presented the details of the ORION-1 Phase II trial interim results of 501 patients given MDCO-PCSK-9si at a Late-Breaker Session at the AHA.
